Physician profile
Miranda Warren
NPI 1528774775
$1,442.76
in general payments reported to CMS, 2019-2025
12 companies · $89.05 in 2025
The $89.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $790 · 2024: $564 · 2025: $89.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.36 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $294.36 | 2023-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $160.44 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $151.90 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $88.88 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.93 | 2023-2024 | Caplyta |
| Gilead Sciences, INC. | $52.17 | 2024 | |
| Lundbeck LLC | $40.48 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $36.65 | 2023-2024 | Austedo Xr, Uzedy |
| Braeburn INC. | $18.82 | 2024 | Brixadi |
| Janssen Biotech, INC. | $18.55 | 2023 | |
| Vanda Pharmaceuticals INC. | $18.22 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.